Yoh Zen

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Andreas A. Prachalias · 5 shared papers, 2021–2026 · strength 1.48
   • Paper Can negative lymph node involvement and resection-free margins (ypT1-3N0R0) compete the disease-free survival benefit o… DOI 10.1016/j.pan.2025.11.020↗
   • Paper Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Cas… DOI 10.7759/cureus.105912↗
   • Paper Complete pathological response in metastatic pancreatic adenocarcinoma following neoadjuvant therapy. DOI 10.1016/j.pan.2025.11.018↗
2. Evangelia Florou · 3 shared papers, 2026 · strength 1.25
   • Paper Can negative lymph node involvement and resection-free margins (ypT1-3N0R0) compete the disease-free survival benefit o… DOI 10.1016/j.pan.2025.11.020↗
   • Paper Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Cas… DOI 10.7759/cureus.105912↗
   • Paper Complete pathological response in metastatic pancreatic adenocarcinoma following neoadjuvant therapy. DOI 10.1016/j.pan.2025.11.018↗
3. Debashis Sarker · 3 shared papers, 2014–2022 · strength 0.26
   • Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9↗
   • Paper Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I stu… DOI 10.1016/j.ejso.2021.05.024↗
   • Paper Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cance… DOI 10.1371/journal.pone.0090948↗
4. Jessica Kristine Nelson · 2 shared papers, 2022 · strength 0.24
   • Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9↗
   • Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7↗
5. Theodore Evan · 2 shared papers, 2022 · strength 0.24
   • Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9↗
   • Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7↗
6. Axel Behrens · 2 shared papers, 2022 · strength 0.24
   • Paper USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic ca… DOI 10.1038/s41467-022-29684-9↗
   • Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7↗
7. Keitaro Sofue · 3 shared papers, 2017–2018 · strength 0.19
   • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
   • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
   • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
8. Mamoru Takenaka · 3 shared papers, 2017–2018 · strength 0.19
   • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
   • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
   • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
9. Atsuhiro Masuda · 3 shared papers, 2017–2018 · strength 0.19
   • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
   • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
   • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
10. Takeshi Azuma · 3 shared papers, 2017–2018 · strength 0.19
    • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
    • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
11. Takashi Kobayashi · 3 shared papers, 2017–2018 · strength 0.19
    • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
    • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
12. Hirochika Toyama · 3 shared papers, 2017–2018 · strength 0.19
    • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
    • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
13. Takumi Fukumoto · 3 shared papers, 2017–2018 · strength 0.19
    • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
    • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
14. Masaru Yoshida · 3 shared papers, 2017–2018 · strength 0.19
    • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
    • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
15. Takuya Ikegawa · 2 shared papers, 2018 · strength 0.13
    • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
16. Takashi Nakagawa · 2 shared papers, 2018 · strength 0.13
    • Paper Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. DOI 10.1016/j.pan.2018.04.005↗
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
17. Yosuke Yagi · 2 shared papers, 2017–2018 · strength 0.12
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
    • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
18. Yonson Ku · 2 shared papers, 2017–2018 · strength 0.12
    • Paper Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mu… DOI 10.1016/j.pan.2017.12.007↗
    • Paper Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. DOI 10.1097/mpa.0000000000000761↗
19. Anguraj Sadanandam · 1 shared paper, 2022 · strength 0.12
    • Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7↗
20. Linxiang Lan · 1 shared paper, 2022 · strength 0.12
    • Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7↗
21. Huafu Li · 1 shared paper, 2022 · strength 0.12
    • Paper GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. DOI 10.1038/s41586-022-04888-7↗
22. Paul J. Ross · 1 shared paper, 2021 · strength 0.11
    • Paper Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I stu… DOI 10.1016/j.ejso.2021.05.024↗
23. Michail Papoulas · 1 shared paper, 2021 · strength 0.11
    • Paper Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I stu… DOI 10.1016/j.ejso.2021.05.024↗
24. Krishna V Menon · 1 shared paper, 2021 · strength 0.11
    • Paper Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I stu… DOI 10.1016/j.ejso.2021.05.024↗
25. Kaushal Kundalia · 1 shared paper, 2021 · strength 0.11
    • Paper Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I stu… DOI 10.1016/j.ejso.2021.05.024↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.